March 10, 2025 11:04 AM EDT

J&J, Protagonist outline first IBD win for oral IL-23 with $5B+ sales potential

Max Gelman

Senior Editor

Johnson & Johnson and Protagonist Therapeutics have bet their oral IL-23 drug will be an immunology blockbuster, and they are now one step closer to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J, Protagonist outline first IBD win for oral IL-23 with $5B+ sales potential

Max Gelman

Senior Editor

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

New Flagship startup aims to trailblaze ‘AI science factories’

Beam shares promising first clinical data on gene editing treatment for a lung and liver disease

Exclusive: FDA blocks drug and device reviewers from taking HHS' buyout offer

Emergent sells once-troubled manufacturing site to Indian CDMO

Sun Pharma to acquire Checkpoint Therapeutics and its anti-PD-L1 antibody

Obesity drug development—still room to grow

J&J, Pro­tag­o­nist out­line first IBD win for oral IL-23 with $5B+ sales po­ten­tial

Senior Editor

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

J&J, Protagonist outline first IBD win for oral IL-23 with $5B+ sales potential